 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H19N5 |
| Molar mass | 293.374 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
ABT-724 is a drug which acts as a dopamine agonist, and is selective for the D4 subtype.[1] It was developed as a possible drug for the treatment of erectile dysfunction,[2] although poor oral bioavailability means alternative drugs such as ABT-670 may be more likely to be developed commercially.[3] Nonetheless, it continues to be used in scientific research into the function of the D4 receptor.[4][5]
See also
- ABT-670
- Bremelanotide
- Cabergoline
- Flibanserin
- Intrinsa
- Melanotan II
- Pramipexole
- PF-219,061
- Tibolone
- UK-414,495
References
- ^ Brioni JD, Moreland RB, Cowart M, Hsieh GC, Stewart AO, Hedlund P, et al. (April 2004). "Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats". Proceedings of the National Academy of Sciences of the United States of America. 101 (17): 6758–6763. Bibcode:2004PNAS..101.6758B. doi:10.1073/pnas.0308292101. PMC 404118. PMID 15087502.
- ^ Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, et al. (July 2004). "Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction". Journal of Medicinal Chemistry. 47 (15): 3853–3864. doi:10.1021/jm030505a. PMID 15239663.
- ^ Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, et al. (December 2006). "Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–7465. doi:10.1021/jm060662k. PMID 17149874.
- ^ Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N, Cussac D (May 2008). "Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells". The International Journal of Neuropsychopharmacology. 11 (3): 293–307. doi:10.1017/S1461145707008061. PMID 17897483.
- ^ Marona-Lewicka D, Chemel BR, Nichols DE (April 2009). "Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI". Psychopharmacology. 203 (2): 265–277. doi:10.1007/s00213-008-1238-0. PMID 18604600.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 22 January 2023, at 15:00